Aditxt, Inc. (ADTX): debt financing — Aditxt to acquire Evofem in stock merger; assumes ~$100M debt, targets women's health market

Aditxt, Inc.

Evofem shareholders to receive 610K shares of Aditxt common and 2,327 shares of Series A-1 preferred.
Aditxt assumes ~$100M senior indebtedness; issues $5M Jan 2024 secured notes, $8M Sep 2024 secured notes, $5M unsecured notes.
Evofem's Phexxi net sales $13.4M for first 9 months 2023; non-hormonal contraceptive market projected $27.7B to $52.2B by 2031.
Closing requires shareholder approvals, SEC S-4 effectiveness, Nasdaq compliance, and warrant/note holder agreements.
Aditxt must provide $3M loan to Evofem by Jan 31, 2024; deal may be terminated if not closed by May 8, 2024.

item 1.01 item 2.03 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.7

Aditxt, Inc. incurred senior notes.

Instrument: senior notes
Event: incurrence

Exact text from the filing

Reference is made to the disclosure under Item 1.01 above with respect to the December 2023 Secured Notes, September 2024 Secured Notes and the Royalty Note

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Aditxt, Inc. entered into Agreement and Plan of Merger with Evofem Biosciences, Inc. valued at Merger Sub will be merged into and with Evofem, with Evofem surviving as a wholly owned subsidiary o (effective 2023-12-11).

Action: entry
Agreement: merger
Counterparty: Evofem Biosciences, Inc.
Value: Merger Sub will be merged into and with Evofem, with Evofem surviving as a wholly owned subsidiary o
Effective: 2023-12-11

Exact text from the filing

On December 11, 2023 (the " Execution Date "), Aditxt, Inc., a Delaware corporation (the " Company ") entered into an Agreement and Plan of Merger (the " Merger Agreement ") with Adicure, Inc., a Delaware corporation and wholly owned subsidiary of the Company (" Merger Sub ") and Evofem Biosciences, Inc., a Delaware corporation (" Evofem "), pursuant to which, Merger Sub will be merged into and with Evofem (the " Merger "), with Evofem surviving the Merger as a wholly owned subsidiary of the Company.

View on SEC.gov

103 debt financings filed in the last 30 days. Browse all debt financings →

Aditxt, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-095155

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.